Michael Kim, MD, on Developing More CREB Inhibitors in Pancreatic Cancer Moving Forward

Video
Conference|American Association for Cancer Research Annual Meeting (AACR)

Kim discussed the need for further CREB inhibitor combinations to target collateral pathways and improve patient outcomes.

Michael Kim, MD, of The University of Texas MD Anderson Cancer Center, spoke with CancerNetwork® at the virtual American Association for Cancer Research Annual Meeting 2021 about the need for more CREB inhibitors to effectively treat patients with pancreatic cancer moving forward.

Transcription:

Work moving forward should figure out what other drugs can be combined with the CREB inhibitor we used [in our study]. There’s only one we could find, so the development of additional CREB inhibitors would be a great step forward. Also, understanding how we can mix other drugs with CREB inhibitors to shut down other collateral pathways important in KRAS signaling [will be essential]. The combination of those 2 might really lead to improved patient outcomes and a better mechanistic understanding of how mutant TP53 and KRAS can be divided and then individually conquered to fight this disease.

Reference:

Kim MP, Li X, Deng J, et al. Mutant p53 and oncogenic KRAS converge on CREB1 to drive pancreatic cancer metastasis. Presented at: AACR Annual Meeting 2021; April 10-15, 2021; virtual. Abstract 2417.

Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Related Content
Sacituzumab Tirumotecan Shows Early Efficacy in Gastric/GEJ Cancers

Sacituzumab Tirumotecan Shows Early Efficacy in Gastric/GEJ Cancers

April 15th 2024
Article

Sacituzumab tirumotecan elicited responses prominently in the second- and third-line and beyond setting and in those with high TROP2 expression.

Diane M. Simeone, MD highlights the importance of multidisciplinary care, surgical practices, and early detection in pancreatic cancer care.

Diane M. Simeone, MD “Thrilled” To Be UCSD Moores Cancer Center Director

February 26th 2024
Podcast

Diane M. Simeone, MD highlights the importance of multidisciplinary care, surgical practices, and early detection in pancreatic cancer care.

Response Observed With Savolitinib Combo in EGFR, MET, Osimertinib-Resistant NSCLC

Response Observed With Savolitinib Combo in EGFR, MET, Osimertinib-Resistant NSCLC

April 13th 2024
Article

A proteogenomic analysis found savolitinib plus osimertinib elicited a response in patients with EGFR-mutated, MET-amplified advanced NSCLC.

Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.

Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy

January 1st 2024
Podcast

Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.

First-in-patient findings support AZD1390 as a potential radiosensitizer during the management of glioblastoma.

AZD1390/Radiation Yields Encouraging Efficacy, Safety in Glioblastoma

April 9th 2024
Article

First-in-patient findings support AZD1390 as a potential radiosensitizer during the management of glioblastoma.

Data from the phase 1/2 KRYSTAL-1 trial may support adagrasib plus cetuximab as a new standard in previously treated metastatic KRAS G12C–mutated CRC.

Adagrasib Combo Yields Encouraging Responses in KRAS G12C–Mutated CRC

April 9th 2024
Article

Data from the phase 1/2 KRYSTAL-1 trial may support adagrasib plus cetuximab as a new standard in previously treated metastatic KRAS G12C–mutated CRC.